Research Analysts’ Weekly Ratings Updates for Zymeworks (ZYME)

Zymeworks (NASDAQ: ZYME) has recently received a number of price target changes and ratings updates:

• 8/10/2026 – Zymeworks had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $44.00 price target on the stock, up from $40.00.
• 8/10/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup Inc..
• 8/7/2026 – Zymeworks was given a new $46.00 price target by Stifel Nicolaus.
• 8/7/2026 – Zymeworks had its price target raised by Wells Fargo & Company from $37.00 to $40.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Zymeworks had its price target raised by Truist Financial Corporation from $31.00 to $32.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Zymeworks had its price target raised by HC Wainwright from $46.00 to $51.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Zymeworks had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Zymeworks had its price target raised by Truist Financial Corporation from $28.00 to $31.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Zymeworks had its price target raised by Wells Fargo & Company from $34.00 to $37.00. They now have an “overweight” rating on the stock.
• 6/30/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup Inc..

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.